An FDA panel has backed the safety and efficacy of Johnson & Johnson's bedaquiline drug for tuberculosis, but also pointed out possible heart and liver-safety issues. The drug works by targeting the adenosine triphosphate synthase enzyme, which the pathogen requires to generate energy.
J&J's tuberculosis drug gets FDA panel support
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan